Drug-related morbidity and mortality. A cost-of-illness model - PubMed (original) (raw)
. 1995 Oct 9;155(18):1949-56.
Affiliations
- PMID: 7575048
Drug-related morbidity and mortality. A cost-of-illness model
J A Johnson et al. Arch Intern Med. 1995.
Abstract
Background: Preventable drug-related morbidity and mortality represent a serious medical problem that urgently requires expert attention. The costs to society of the misuse of prescription medications, in terms of morbidity, mortality, and treatment, can be immense. To date, research has primarily documented increased rates of hospitalization secondary to medication noncompliance and/or adverse drug effects.
Objectives: To develop a conceptual model of drug-related morbidity and mortality, and to estimate the associated costs in the ambulatory setting in the United States.
Methods: A probability pathway model was developed to estimate the cost of drug-related morbidity and mortality in the United States. Pharmacist practitioners were surveyed to determine conditional probabilities of therapeutic outcomes owing to drug therapy. Health care utilization and associated costs owing to negative therapeutic outcomes were estimated.
Results: Drug-related morbidity and mortality was estimated to cost 76.6billionintheambulatorysettingintheUnitedStates.Thelargestcomponentofthistotalcostwasassociatedwithdrug−relatedhospitalizations.Whenassumptionsofthemodelwerevaried,theestimatedcostrangedfromaconservativeestimateof76.6 billion in the ambulatory setting in the United States. The largest component of this total cost was associated with drug-related hospitalizations. When assumptions of the model were varied, the estimated cost ranged from a conservative estimate of 76.6billionintheambulatorysettingintheUnitedStates.Thelargestcomponentofthistotalcostwasassociatedwithdrug−relatedhospitalizations.Whenassumptionsofthemodelwerevaried,theestimatedcostrangedfromaconservativeestimateof30.1 to $136.8 billion in a worst-case scenario.
Conclusions: The cost of drug-related morbidity and mortality in the ambulatory setting in the United States is considerable and should be considered in health policy decisions with regard to pharmaceutical benefits. Policies and services should be developed to reduce and prevent drug-related morbidity and mortality.
Comment in
- To err is human.
Bootman JL. Bootman JL. Arch Intern Med. 2000 Nov 27;160(21):3189. doi: 10.1001/archinte.160.21.3189. Arch Intern Med. 2000. PMID: 11088077 No abstract available.
Similar articles
- The health care cost of drug-related morbidity and mortality in nursing facilities.
Bootman JL, Harrison DL, Cox E. Bootman JL, et al. Arch Intern Med. 1997 Oct 13;157(18):2089-96. Arch Intern Med. 1997. PMID: 9382665 - The economic burden of depression in 1990.
Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Greenberg PE, et al. J Clin Psychiatry. 1993 Nov;54(11):405-18. J Clin Psychiatry. 1993. PMID: 8270583 - Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ, Scuffham PA, McCollam PL, Newby DE. Taylor MJ, et al. Curr Med Res Opin. 2007 Mar;23(3):495-503. doi: 10.1185/030079906X167462. Curr Med Res Opin. 2007. PMID: 17355731 - Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review. - Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX, Liu GG, Christensen DB, Fu AZ. Sun SX, et al. Curr Med Res Opin. 2007 Oct;23(10):2305-12. doi: 10.1185/030079907X226050. Curr Med Res Opin. 2007. PMID: 17697454 Review.
Cited by
- Acute COPD exacerbations and in-hospital treatment-related problems: An observational study.
Awwad O, Abu Farha R, Altaharwah A, Sharaya S, Naser AY, Tabaza H. Awwad O, et al. PLoS One. 2024 Jun 6;19(6):e0305011. doi: 10.1371/journal.pone.0305011. eCollection 2024. PLoS One. 2024. PMID: 38843229 Free PMC article. - Development and Evaluation of a Reliable Medication Management Self-Assessment Checklist.
Isetts BJ, Talley KM, Brearley AM. Isetts BJ, et al. Innov Pharm. 2024 Mar 18;15(1):10.24926/iip.v15i1.5802. doi: 10.24926/iip.v15i1.5802. eCollection 2024. Innov Pharm. 2024. PMID: 38779108 Free PMC article. - Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient population.
Dagenais S, Lee C, Cronenberger C, Wang E, Sahasrabudhe V. Dagenais S, et al. Clin Transl Sci. 2024 Mar;17(3):e13741. doi: 10.1111/cts.13741. Clin Transl Sci. 2024. PMID: 38445532 Free PMC article. - Clinical and economic impact of adverse drug reactions in hospitalised patients: prospective matched nested case-control study in Ethiopia.
Sendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA. Sendekie AK, et al. BMJ Open. 2023 Jun 6;13(6):e073777. doi: 10.1136/bmjopen-2023-073777. BMJ Open. 2023. PMID: 37280017 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical